Summary
Anatomic indicators of increased breast cancer risk have regularly been identified as hyperplastic lesions, analogous to other body sites. Most of these have been shown to indicate a later increased risk anywhere in either breast and should thus be regarded as indicators or markers of increased risk. Unfortunately, these are largely identified incidentally to current methods of detection. Specific combined histologic and cytologic criteria for the definition of these lesions have been evaluated for both their reproducibility of diagnosis and outcome variables. Several studies agree that usual patterns of hyperplasia of at least moderate degree indicate an increased risk of later breast carcinoma between 1.5 and 2 times that of the general population. The specifically defined examples of atypical hyperplasia, lesions of relative rarity, are found in 4–5% of biopsies (depending upon method of detection) and recognize a risk in the range of 4–5 times that of the general population controlled for age and duration of follow-up. Thus, several cohort studies using comparable criteria for definition of the anatomic lesions have found similar clinical outcomes.
Other approaches to histologic definition have produced a lesser degree of separation between the non “atypical” and other forms of hyperplasia. Although it is not clear whether we are dealing with continuous variables or discrete histologic/cytologic variables, it is clear that when combined criteria are used, a greater degree of predictability is obtained.
Other related risk features include most predominantly family history, which when present with atypical hyperplasia indicates an increased risk beyond that of either alone. Other means of detection of these various lesions, such as fine needle aspiration cytology, have not been verified.
True non-obligate precursors of breast cancer are probably confined to low grade and non-comedo ductal carcinomas of the breast.
Similar content being viewed by others
References
Foote FW, Stewart FW: Comparative studies of cancerous versus noncancerous breasts. Ann Surg 121:6–53,197–222, 1945
Donnelly PK, Baker KW, Carney JA, O'Fallon WM: Benign breast lesions and subsequent breast carcinoma in Rochester, Minnesota. Mayo Clin Proc 50:650–656, 1975
Wellings SR, Jensen HM, Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. JNCI 55:231–273, 1975
Boyd NF, Jensen HM, Cooke G, Han HL: Relationship between mammographic and histological risk factors for breast cancer. JNCI 84:1170–1179, 1992
Page DL, Vander Zwaag R, Rogers LW, Williams LT, Walker WE, Hartmann WH: Relation between component parts of fibrocystic disease complex and breast cancer. JNCI 61:1055–1063, 1978
Page DL, Dupont WD, Rogers LW, Rados MS: Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55:2698–2708, 1985
Dupont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151, 1985
Page DL, Rogers LW: Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 23:1095–1097, 1992
Page DL, Anderson TJ, Rogers LW: Epithelial hyperplasia.In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast. Churchill Livingstone, Edinburgh, 1988, pp 120–156
Page DL, Anderson TJ, Rogers LW: Carcinoma in situ (CIS).In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast. Churchill Livingstone, Edinburgh, 1988, pp 157–192
London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and risk of breast cancer. JAMA 267:941–944, 1992
Palli D, Rosselli del Turco M, Simoncini R, Bianchi S: Benign breast disease and breast cancer: A case-control study in a cohort in Italy. Int J Cancer 47:703–706, 1991
Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71:1258–1265, 1993
Page DL, Dupont WD: Anatomic markers of human premalignancy and risk of breast cancer. Cancer 66:1326–1335, 1990
Page DL, Dupont WD, Rogers LW, Landenberger M: Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49:751–758, 1982
Hutter RVP: Consensus meeting. Is “fibrocystic disease” of the breast precancerous? Arch Path Lab Med 110:171–173, 1986
Page DL, Dupont WD: Histologic indicators of breast cancer risk. Bull Am Coll Surg 76:16–23, 1991
Tavassoli FA, Norris HJ: A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 65:518–529, 1990
Page DL, Dupont WD: Premalignant conditions and markers of elevated risk in the breast and their management. Surg Clin N Am 70:831–851, 1990
Eusebi V, Foschini MA, Cook MG, Berrino F, Azzopardi JG: Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Sem Diag Path 6:165–173,1989
Clement PB, Young RH, Azzopardi JG: Collagenous spherulosis of the breast. Am J Surg Pathol 11:411–417, 1987
Wells CA, Wells CW, Yeomans P, Viña M, Jordan S, D'Ardenne AJ: Spherical connective tissue inclusions in epithelial hyperplasia of the breast (“collagenous spherulosis”). J Clin Pathol 43:905–908, 1990
Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy G: Prognostic significance of benign proliferative breast disease. Cancer 71:3896–3907, 1993
Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR: A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 128:467–477, 1988
Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, Gelman R, Page DL: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 16:1133–1143, 1992
Page DL, Dupont WD, Rogers LW: Breast cancer risk of lobular-based hyperplasia after biopsy: “ductal” pattern lesions. Cancer Detect Prev 9:441–448, 1986
Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW: Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22:1232–1239, 1991
Haagensen CD, Lane N, Lattes R, Bodian C: Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42:737–769, 1978
Rosen PP, Lieberman PH, Braun DW Jr, Kosloff C, Adair F: Lobular carcinoma in situ of the breast: detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 2:225–251, 1978
Page DL, Dupont WD, Rogers LW: Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. Hum Pathol 19:201–207, 1988
Jensen RA, Page DL, Dupont WD, Rogers LW: Invasive breast cancer risk in women with sclerosing adenosis. Cancer 64:1977–1983, 1989
McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D, Cancer and Steroid Hormone Study Group: Histologic types of benign breast disease and the risk for breast cancer. Cancer 69:1408–1414, 1992
Dupont WD: Converting relative risks to absolute risks: A graphical approach. Stat Med 8:641–651, 1989
Shack RB, Page DL: The patient at risk for breast cancer: Pathologic and surgical considerations. Perspect Plast Surg 2:43–62, 1988
Wapnir IL, Rabinowitz B, Greco R,: A reappraisal of prophylactic mastectomy. Surg Gynecol Obstet 171:171–184, 1990
Brinton LA, Schairer C: Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 15:66–79, 1993
Dupont WD, Page DL, Rogers LW, Parl FF: Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 63:948–957, 1989
Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72, 1991
Dupont WD, Page DL: Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 20:723–725, 1989
Rubin E, Alexander RW, Visscher DW, Urist MM, Maddox WA: Proliferative disease and atypia in biopsies performed for mammographically detected nonpalpable lesions. Cancer 61:2077–2082, 1988
Sonnenfeld MR, Frenna TH, Weidner N, Meyer JE: Lobular carcinoma in situ: Mammographic-pathologic correlation of results of needle-directed biopsy. Radiology 181:363–367, 1991
Beute BJ, Kalisher L, Hutter RVP: Lobular carcinoma in situ of the breast: Clinical, pathologic and mammographic features. Am J Roentgenol 157:257–265, 1991
Abendroth CS, Wang HH, Ducatman BS: Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on fine-needle aspiration biopsy specimens. Am J Clin Pathol 96:654–659, 1991
Stanley MW, Henry-Stanley MJ, Zera R: Atypia in breast fine-needle aspiration smears correlates poorly with the presence of a prognostically significant proliferative lesion of ductal epithelium. Hum Pathol 24:630–635, 1993
Markovic-Glamocak M, Boban D, Sucic M, Oberman B, Scukanec-Spoljar M: Significance of proliferative epithelial changes in breast fine-needle aspiration. Cancer 70:781–783, 1992
Page DL, Dupont WD: Proliferative breast disease: Diagnosis and implications. Science 253:915, 1991
Beute BJ, Kalisher L, Hutter RVP: Lobular carcinoma in situ of the breast: Clinical, pathologic, and mammographic features. Am J Roentgenol 157:257–265, 1991
Petrakis NL: Nipple aspirate fluid in epidemologic studies of breast disease. Epidemiol Rev 15:188–195, 1993
Van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, Recht A: Ductal carcinoma in-situ of the breast: Second EORTC consensus meeting. Eur J Cancer 28:626–629, 1992
Gump FE, Jicha DL, Ozzello L: Ductal carcinoma in situ (DCIS): A revised concept. Surgery 102:790–795, 1987
Lagios MD, Margolin FR, Westdahl PR, Rose MR: Mammographically detected duct carcinoma in situ. Cancer 63:618–624, 1989
Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF: Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239:1863–1867, 1978
Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS: Subclinical ductal carcinoma in situ of the breast: Treatment by local excision and surveillance alone. Cancer 70:2468–2474, 1992
Bellamy COC, McDonald C, Salter DM, Chetty U, Anderson TJ: Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. Hum Pathol 24:16–23, 1993
Lagios MD: Duct carcinoma in situ: Pathology and treatment. Surg Clin N Am 70:853–871, 1990
Kodlin D, Winger EE, Morgenstern NL, Chen U: Chronic mastopathy and breast cancer: a follow-up study. Cancer 39:2603–2607, 1977
Krieger N, Hiatt RA: Risk of breast cancer after benign breast diseases: Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 135:619–631,1992
Author information
Authors and Affiliations
Additional information
Supported in part by National Cancer Institute grant R01-CA50468
Rights and permissions
About this article
Cite this article
Page, D.L., Dupont, W.D. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Tr 28, 157–166 (1993). https://doi.org/10.1007/BF00666428
Issue Date:
DOI: https://doi.org/10.1007/BF00666428